Adeno-associated virus (AAV) vectors in cancer gene therapy

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 287-301

  Santiago Ortiz, Jorge L ^a   Schaffer, David V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California at Berkeley   (United States)

Author keywords

AAV; Adeno associated virus; Cancer; Gene delivery; Gene delivery vectors; Gene therapy

Indexed keywords

CELL ENGINEERING; DISEASE CONTROL; DISEASES; GENE TRANSFER; GENES; VECTORS; VIRUSES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS VECTORS; CANCER; CANCER GENE THERAPY; CLINICAL DEVELOPMENT; GENE DELIVERY; GENE DELIVERY VECTORS; THERAPEUTIC EFFICACY;

GENE THERAPY;

ANTIGEN; CYTOKINE; PARVOVIRUS VECTOR; RNA; CAPSID PROTEIN;

ADENO ASSOCIATED VIRUS; ANTIANGIOGENIC THERAPY; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER MODEL; CELL STIMULATION; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR SUPPRESSOR GENE; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; NEOPLASM; PROCEDURES; PROTEIN ENGINEERING; TRANSGENE;

CAPSID PROTEINS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PROTEIN ENGINEERING; TRANSGENES;

EID: 84957831557     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.01.001     Document Type: Article

References (190)

1. [1] A.C. Society, Cancer Facts & Figures 2015. 2015, American Cancer Society, Atlanta, GA.
2. [2] Venere, M., Fine, H.A., Dirks, P.B., Rich, J.N., Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia 59 (2011), 1148–1154.
3. [3] Cross, D., Burmester, J.K., Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 4 (2006), 218–227.
4. [4] Simonelli, F., Maguire, A.M., Testa, F., Pierce, E.A., Mingozzi, F., Bennicelli, J.L., Rossi, S., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Redmond, T.M., Zhu, X., Shindler, K.S., Ying, G.S., Ziviello, C., Acerra, C., Wright, J.F., McDonnell, J.W., High, K.A., Bennett, J., Auricchio, A., Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18 (2010), 643–650.
5. [5] Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., O'Beirne, J., Smith, K., Pasi, J., Glader, B., Rustagi, P., Ng, C.Y., Kay, M.A., Zhou, J., Spence, Y., Morton, C.L., Allay, J., Coleman, J., Sleep, S., Cunningham, J.M., Srivastava, D., Basner-Tschakarjan, E., Mingozzi, F., High, K.A., Gray, J.T., Reiss, U.M., Nienhuis, A.W., Davidoff, A.M., Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365 (2011), 2357–2365.
6. [6] Indications Addressed by Gene Therapy Clinical Trials, in. The Journal of Gene Medicine, 2015 www.wiley.co.uk/genmed/clinical [2015, August].
7. [7] Ledford, H., Cancer-fighting viruses win approval. Nature 526 (2015), 622–623.
8. [8] Gao, X., Kim, K.S., Liu, D., Nonviral gene delivery: what we know and what is next. AAPS J. 9 (2007), E92–104.
9. [9] Giacca, M., Zacchigna, S., Virus-mediated gene delivery for human gene therapy. J. Control. Release 161 (2012), 377–388.
10. [10] Kotterman, M.A., Schaffer, D.V., Engineering adeno-associated viruses for clinical gene therapy. Nat. Rev. Genet. 15 (2014), 445–451.
11. [11] Testa, F., Maguire, A.M., Rossi, S., Pierce, E.A., Melillo, P., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Acerra, C., Wright, J.F., Wellman, J., High, K.A., Auricchio, A., Bennett, J., Simonelli, F., Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
12. [12] Dalkara, D., Sahel, J.A., Gene therapy for inherited retinal degenerations. C. R. Biol. 337 (2014), 185–192.
13. [13] Ohmori, T., Mizukami, H., Ozawa, K., Sakata, Y., Nishimura, S., New approaches to gene and cell therapy for hemophilia. J. Thromb. Haemost. 13:Suppl. 1 (2015), S133–S142.
14. [14] Carpentier, A.C., Frisch, F., Labbe, S.M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., Gaudet, D., Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97 (2012), 1635–1644.
15. [15] Bartel, M.A., Weinstein, J.R., Schaffer, D.V., Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 19 (2012), 694–700.
16. [16] Sonntag, F., Schmidt, K., Kleinschmidt, J.A., A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 10220–10225.
17. [17] Bartlett, J.S., Samulski, R.J., McCown, T.J., Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 9 (1998), 1181–1186.
18. [18] Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K.J., Engelhardt, J.F., Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72 (1998), 8568–8577.
19. [19] Kotin, R.M., Siniscalco, M., Samulski, R.J., Zhu, X.D., Hunter, L., Laughlin, C.A., McLaughlin, S., Muzyczka, N., Rocchi, M., Berns, K.I., Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 2211–2215.
20. [20] Ellis, B.L., Hirsch, M.L., Barker, J.C., Connelly, J.P., Steininger, R.J. III, Porteus, M.H., A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol. J., 10, 2013, 74.
21. [21] Berns, K.I., Linden, R.M., The cryptic life style of adeno-associated virus. BioEssays 17 (1995), 237–245.
22. [22] Flotte, T.R., Afione, S.A., Zeitlin, P.L., Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am. J. Respir. Cell Mol. Biol. 11 (1994), 517–521.
23. [23] Mancheno-Corvo, P., Martin-Duque, P., Viral gene therapy. Clin. Transl. Oncol. 8 (2006), 858–867.
24. [24] McCarty, D.M., Monahan, P.E., Samulski, R.J., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8 (2001), 1248–1254.
25. [25] Asokan, A., Schaffer, D.V., Samulski, R.J., The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20 (2012), 699–708.
26. [26] Jacobson, S.G., Cideciyan, A.V., Ratnakaram, R., Heon, E., Schwartz, S.B., Roman, A.J., Peden, M.C., Aleman, T.S., Boye, S.L., Sumaroka, A., Conlon, T.J., Calcedo, R., Pang, J.J., Erger, K.E., Olivares, M.B., Mullins, C.L., Swider, M., Kaushal, S., Feuer, W.J., Iannaccone, A., Fishman, G.A., Stone, E.M., Byrne, B.J., Hauswirth, W.W., Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130 (2012), 9–24.
27. [27] MacLaren, R.E., Groppe, M., Barnard, A.R., Cottriall, C.L., Tolmachova, T., Seymour, L., Clark, K.R., During, M.J., Cremers, F.P., Black, G.C., Lotery, A.J., Downes, S.M., Webster, A.R., Seabra, M.C., Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383 (2014), 1129–1137.
28. [28] Stroes, E.S., Nierman, M.C., Meulenberg, J.J., Franssen, R., Twisk, J., Henny, C.P., Maas, M.M., Zwinderman, A.H., Ross, C., Aronica, E., High, K.A., Levi, M.M., Hayden, M.R., Kastelein, J.J., Kuivenhoven, J.A., Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 2303–2304.
29. [29] Gaudet, D., Methot, J., Dery, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., Sier-Ferreira, V., van Deventer, S., Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 20 (2013), 361–369.
30. [30] Nicklin, S.A., Dishart, K.L., Buening, H., Reynolds, P.N., Hallek, M., Nemerow, G.R., Von Seggern, D.J., Baker, A.H., Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett. 201 (2003), 165–173.
31. [31] Teschendorf, C., Emons, B., Muzyczka, N., Graeven, U., Schmiegel, W., Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells. Anticancer Res. 30 (2010), 1931–1935.
32. [32] Kohlschutter, J., Michelfelder, S., Trepel, M., Novel cytotoxic vectors based on adeno-associated virus. Toxins 2 (2010), 2754–2768.
33. [33] Li, C., Bowles, D.E., van Dyke, T., Samulski, R.J., Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 12 (2005), 913–925.
34. [34] Zhong, L., Li, B., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R.W., Zolotukhin, I., Warrington, K.H. Jr., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., Muzyczka, N., Srivastava, A., Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 7827–7832.
35. [35] Lochrie, M.A., Tatsuno, G.P., Christie, B., McDonnell, J.W., Zhou, S., Surosky, R., Pierce, G.F., Colosi, P., Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80 (2006), 821–834.
36. [36] Koerber, J.T., Maheshri, N., Kaspar, B.K., Schaffer, D.V., Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles. Nat. Protoc. 1 (2006), 701–706.
37. [37] Koerber, J.T., Jang, J.H., Schaffer, D.V., DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16 (2008), 1703–s1709.
38. [38] Koerber, J.T., Schaffer, D.V., Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties. Methods Mol. Biol. 434 (2008), 161–170.
39. [39] Santiago-Ortiz, J., Ojala, D.S., Westesson, O., Weinstein, J.R., Wong, S.Y., Steinsapir, A., Kumar, S., Holmes, I., Schaffer, D.V., AAV ancestral reconstruction library enables selection of broadly infectious viral variants. Gene Ther., 2015.
40. [40] Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., Buning, H., Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J. Gene Med. 8 (2006), 155–162.
41. [41] Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A.C., Plovie, E., Xiao, R., Vandenberghe, L.H., In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 12 (2015), 1056–1068.
42. [42] Grimm, D., Lee, J.S., Wang, L., Desai, T., Akache, B., Storm, T.A., Kay, M.A., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008), 5887–5911.
43. [43] Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J.S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Redmond, D.E. Jr., McCown, T.J., Petermann, K.B., Sharpless, N.E., Samulski, R.J., Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16 (2008), 1252–1260.
44. [44] Muller, O.J., Kaul, F., Weitzman, M.D., Pasqualini, R., Arap, W., Kleinschmidt, J.A., Trepel, M., Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21 (2003), 1040–1046.
45. [45] Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., Muller, O.J., Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19 (2012), 800–809.
46. [46] Excoffon, K.J., Koerber, J.T., Dickey, D.D., Murtha, M., Keshavjee, S., Kaspar, B.K., Zabner, J., Schaffer, D.V., Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 3865–3870.
47. [47] Jang, J.H., Koerber, J.T., Kim, J.S., Asuri, P., Vazin, T., Bartel, M., Keung, A., Kwon, I., Park, K.I., Schaffer, D.V., An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol. Ther. 19 (2011), 667–675.
48. [48] Asuri, P., Bartel, M.A., Vazin, T., Jang, J.H., Wong, T.B., Schaffer, D.V., Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol. Ther. 20 (2012), 329–338.
49. [49] Dalkara, D., Byrne, L.C., Klimczak, R.R., Visel, M., Yin, L., Merigan, W.H., Flannery, J.G., Schaffer, D.V., In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med., 5, 2013 (189ra176).
50. [50] Klimczak, R.R., Koerber, J.T., Dalkara, D., Flannery, J.G., Schaffer, D.V., A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat muller cells. PLoS One, 4, 2009, e7467.
51. [51] Dalkara, D., Kolstad, K.D., Guerin, K.I., Hoffmann, N.V., Visel, M., Klimczak, R.R., Schaffer, D.V., Flannery, J.G., AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol. Ther. 19 (2011), 1602–1608.
52. [52] Koerber, J.T., Klimczak, R., Jang, J.H., Dalkara, D., Flannery, J.G., Schaffer, D.V., Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther. 17 (2009), 2088–2095.
53. [53] Maheshri, N., Koerber, J.T., Kaspar, B.K., Schaffer, D.V., Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24 (2006), 198–204.
54. [54] Shin, B.K., Wang, H., Yim, A.M., Le Naour, F., Brichory, F., Jang, J.H., Zhao, R., Puravs, E., Tra, J., Michael, C.W., Misek, D.E., Hanash, S.M., Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 278 (2003), 7607–7616.
55. [55] Buonaguro, L., Petrizzo, A., Tornesello, M.L., Buonaguro, F.M., Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18 (2011), 23–34.
56. [56] Novellino, L., Castelli, C., Parmiani, G., A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54 (2005), 187–207.
57. [57] Arap, W., Pasqualini, R., Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998), 377–380.
58. [58] Hajitou, A., Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector. Adv. Genet. 69 (2010), 65–82.
59. [59] Grifman, M., Trepel, M., Speece, P., Gilbert, L.B., Arap, W., Pasqualini, R., Weitzman, M.D., Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3 (2001), 964–975.
60. [60] Zhang, X., Xu, W., Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design. Curr. Med. Chem. 15 (2008), 2850–2865.
61. [61] Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
62. [62] Shi, W., Bartlett, J.S., RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7 (2003), 515–525.
63. [63] Munch, R.C., Janicki, H., Volker, I., Rasbach, A., Hallek, M., Buning, H., Buchholz, C.J., Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21 (2013), 109–118.
64. [64] Lee, H.S., Kim, J.Y., Lee, W.I., Kim, S.J., Ko, M.J., Jeong, S., Park, K., Choe, H., Lee, H., Acquisition of selective antitumoral effects of recombinant adeno-associated virus by genetically inserting tumor-targeting peptides into capsid proteins. Oncol. lett. 2 (2011), 1113–1119.
65. [65] Cheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L.G., Gee, S.W., McGoogan, K.E., Aslanidi, G.V., Park, M., Stacpoole, P.W., Siemann, D., Liu, C., Srivastava, A., Ling, C., Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther. 19 (2012), 375–384.
66. [66] Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., Aslanidi, G.V., Zhong, L., Gao, G., Srivastava, A., Ling, C., Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25 (2014), 1023–1034.
67. [67] Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
68. [68] Pandya, J., Ortiz, L., Ling, C., Rivers, A.E., Aslanidi, G., Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol. Cell Biol. 92 (2014), 116–123.
69. [69] Judd, J., Ho, M.L., Tiwari, A., Gomez, E.J., Dempsey, C., Van Vliet, K., Igoshin, O.A., Silberg, J.J., Agbandje-McKenna, M., Suh, J., Tunable protease-activatable virus nanonodes. ACS Nano 8 (2014), 4740–4746.
70. [70] Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002), 161–174.
71. [71] Peng, K.W., Morling, F.J., Cosset, F.L., Murphy, G., Russell, S.J., A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum. Gene Ther. 8 (1997), 729–738.
72. [72] Michelfelder, S., Kohlschutter, J., Skorupa, A., Pfennings, S., Muller, O., Kleinschmidt, J.A., Trepel, M., Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One, 4, 2009, e5122.
73. [73] Maguire, C.A., Gianni, D., Meijer, D.H., Shaket, L.A., Wakimoto, H., Rabkin, S.D., Gao, G., Sena-Esteves, M., Directed evolution of adeno-associated virus for glioma cell transduction. J. Neuro-Oncol. 96 (2010), 337–347.
74. [74] Robson, T., Hirst, D.G., Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003 (2003), 110–137.
75. [75] Rajendran, S., Collins, S., van Pijkeren, J.P., O'Hanlon, D., O'Sullivan, G.C., Tangney, M., Targeting of breast metastases using a viral gene vector with tumour-selective transcription. Anticancer Res. 31 (2011), 1627–1635.
76. [76] Kyo, S., Takakura, M., Fujiwara, T., Inoue, M., Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 99 (2008), 1528–1538.
77. [77] Watanabe, M., Ueki, H., Ochiai, K., Huang, P., Kobayashi, Y., Nasu, Y., Sasaki, K., Kaku, H., Kashiwakura, Y., Kumon, H., Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging. Oncol. Rep. 26 (2011), 769–775.
78. [78] Della Peruta, M., Badar, A., Rosales, C., Chokshi, S., Kia, A., Nathwani, D., Galante, E., Yan, R., Arstad, E., Davidoff, A.M., Williams, R., Lythgoe, M.F., Nathwani, A.C., Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. Hum. Gene Ther. 26 (2015), 94–103.
79. [79] McIntosh, J., Lenting, P.J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E.G., Christophe, O.D., McVey, J.H., Waddington, S., Nienhuis, A.W., Gray, J.T., Fagone, P., Mingozzi, F., Zhou, S.Z., High, K.A., Cancio, M., Ng, C.Y., Zhou, J., Morton, C.L., Davidoff, A.M., Nathwani, A.C., Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121 (2013), 3335–3344.
80. [80] Al-Husein, B., Abdalla, M., Trepte, M., Deremer, D.L., Somanath, P.R., Antiangiogenic therapy for cancer: an update. Pharmacotherapy 32 (2012), 1095–1111.
81. [81] Mahendra, G., Kumar, S., Isayeva, T., Mahasreshti, P.J., Curiel, D.T., Stockardt, C.R., Grizzle, W.E., Alapati, V., Singh, R., Siegal, G.P., Meleth, S., Ponnazhagan, S., Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 12 (2005), 26–34.
82. [82] Takei, Y., Mizukami, H., Saga, Y., Yoshimura, I., Hasumi, Y., Takayama, T., Kohno, T., Matsushita, T., Okada, T., Kume, A., Suzuki, M., Ozawa, K., Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int. J. Cancer 120 (2007), 278–284.
83. [83] Li, B., Lalani, A.S., Harding, T.C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M.J., Simmons, A.D., Jooss, K., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12 (2006), 6808–6816.
84. [84] Lin, J., Lalani, A.S., Harding, T.C., Gonzalez, M., Wu, W.W., Luan, B., Tu, G.H., Koprivnikar, K., VanRoey, M.J., He, Y., Alitalo, K., Jooss, K., Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65 (2005), 6901–6909.
85. [85] Takahashi, K., Mizukami, H., Saga, Y., Takei, Y., Urabe, M., Kume, A., Machida, S., Fujiwara, H., Suzuki, M., Ozawa, K., Suppression of lymph node and lung metastases of endometrial cancer by muscle-mediated expression of soluble vascular endothelial growth factor receptor-3. Cancer Sci. 104 (2013), 1107–1111.
86. [86] Cai, J., Jiang, W.G., Grant, M.B., Boulton, M., Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J. Biol. Chem. 281 (2006), 3604–3613.
87. [87] He, S.S., Shi, H.S., Yin, T., Li, Y.X., Luo, S.T., Wu, Q.J., Lu, L., Wei, Y.Q., Yang, L., AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits lewis lung carcinoma growth in mice. Oncol. Rep. 27 (2012), 1142–1148.
88. [88] He, S.S., Wu, Q.J., Gong, C.Y., Luo, S.T., Zhang, S., Li, M., Lu, L., Wei, Y.Q., Yang, L., Enhanced efficacy of combination therapy with adenoassociated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of lewis lung carcinoma. Mol. Med. Rep. 9 (2014), 2069–2076.
89. [89] Fang, J., Qian, J.J., Yi, S., Harding, T.C., Tu, G.H., VanRoey, M., Jooss, K., Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23 (2005), 584–590.
90. [90] Watanabe, M., Boyer, J.L., Crystal, R.G., AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther. 17 (2010), 1042–1051.
91. [91] Xie, Y., Hicks, M.J., Kaminsky, S.M., Moore, M.A., Crystal, R.G., Rafii, A., AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecol. Oncol. 135 (2014), 325–332.
92. [92] Folkman, J., Angiogenesis inhibitors: a new class of drugs. Cancer Biol. Ther. 2 (2003), S127–S133.
93. [93] Pan, J.G., Zhou, X., Zeng, G.W., Han, R.F., Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumour Biol. 32 (2011), 301–310.
94. [94] Pan, J.G., Zhou, X., Zeng, G.W., Han, R.F., Potent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivo. J. Surg. Oncol. 105 (2012), 249–257.
95. [95] Sun, X., Krissansen, G.W., Fung, P.W., Xu, S., Shi, J., Man, K., Fan, S.T., Xu, R., Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int. J. Cancer 113 (2005), 670–677.
96. [96] Isayeva, T., Ren, C., Ponnazhagan, S., Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer. Clin. Cancer Res. 11 (2005), 1342–1347.
97. [97] Isayeva, T., Ren, C., Ponnazhagan, S., Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther. 14 (2007), 138–146.
98. [98] Isayeva, T., Chanda, D., Kallman, L., Eltoum, I.E., Ponnazhagan, S., Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res. 67 (2007), 5789–5797.
99. [99] Zhang, X., Xu, J., Lawler, J., Terwilliger, E., Parangi, S., Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin. Cancer Res. 13 (2007), 3968–3976.
100. [100] Subramanian, I.V., Ghebre, R., Ramakrishnan, S., Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther. 12 (2005), 30–38.
101. [101] Subramanian, I.V., Bui Nguyen, T.M., Truskinovsky, A.M., Tolar, J., Blazar, B.R., Ramakrishnan, S., Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 66 (2006), 4319–4328.
102. [102] Yanamandra, N., Kondraganti, S., Gondi, C.S., Gujrati, M., Olivero, W.C., Dinh, D.H., Rao, J.S., Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int. J. Cancer 115 (2005), 998–1005.
103. [103] Bui Nguyen, T.M., Subramanian, I.V., Xiao, X., Nguyen, P., Ramakrishnan, S., Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. Gene Ther. 17 (2010), 606–615.
104. [104] Ruan, Q., Xi, L., Boye, S.L., Han, S., Chen, Z.J., Hauswirth, W.W., Lewin, A.S., Boulton, M.E., Law, B.K., Jiang, W.G., Jiang, H., Cai, J., Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development. Cancer Lett. 332 (2013), 120–129.
105. [105] Cai, K.X., Tse, L.Y., Leung, C., Tam, P.K., Xu, R., Sham, M.H., Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin. Cancer Res. 14 (2008), 939–949.
106. [106] Kuo, C.H., Chang, B.I., Lee, F.T., Chen, P.K., Lee, J.S., Shi, G.Y., Wu, H.L., Development of recombinant AAV2/8 carrying kringle domains of human plasminogen for sustained expression and cancer therapy. Hum. Gene Ther., 2015.
107. [107] Kroeger, K.M., Muhammad, A.K., Baker, G.J., Assi, H., Wibowo, M.K., Xiong, W., Yagiz, K., Candolfi, M., Lowenstein, P.R., Castro, M.G., Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov. Med. 10 (2010), 293–304.
108. [108] Chen, C.Y., Chang, Y.N., Ryan, P., Linscott, M., McGarrity, G.J., Chiang, Y.L., Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the “bystander effect”. Hum. Gene Ther. 6 (1995), 1467–1476.
109. [109] Li, Z.B., Zeng, Z.J., Chen, Q., Luo, S.Q., Hu, W.X., Recombinant AAV-mediated HSVtk gene transfer with direct intratumoral injections and Tet-on regulation for implanted human breast cancer. BMC Cancer, 6, 2006, 66.
110. [110] Zeng, Z.J., Xiang, S.G., Xue, W.W., Li, H.D., Ma, N., Ren, Z.J., Xu, Z.J., Jiao, C.H., Wang, C.Y., Hu, W.X., The cell death and DNA damages caused by the Tet-On regulating HSV-tk/GCV suicide gene system in MCF-7 cells. Biomed. Pharmacother. 68 (2014), 887–892.
111. [111] Kim, J.Y., Kim, J.H., Khim, M., Lee, H.S., Jung, J.H., Moon, D.H., Jeong, S., Lee, H., Persistent anti-tumor effects via recombinant adeno-associated virus encoding herpes thymidine kinase gene monitored by PET-imaging. Oncol. Rep. 25 (2011), 1263–1269.
112. [112] Griffith, T.S., Stokes, B., Kucaba, T.A., Earel, J.K. Jr., VanOosten, R.L., Brincks, E.L., Norian, L.A., TRAIL gene therapy: from preclinical development to clinical application. Curr. Gene Ther. 9 (2009), 9–19.
113. [113] Ma, H., Liu, Y., Liu, S., Kung, H.F., Sun, X., Zheng, D., Xu, R., Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int. J. Cancer 116 (2005), 314–321.
114. [114] Ma, H., Liu, Y., Liu, S., Xu, R., Zheng, D., Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 42 (2005), 1355–1363.
115. [115] Shi, J., Zheng, D., Liu, Y., Sham, M.H., Tam, P., Farzaneh, F., Xu, R., Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 65 (2005), 1687–1692.
116. [116] Yoo, J., Choi, S., Hwang, K.S., Cho, W.K., Jung, C.R., Kwon, S.T., Im, D.S., Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J. Gene Med. 8 (2006), 163–174.
117. [117] Wang, Y., Huang, F., Cai, H., Zhong, S., Liu, X., Tan, W.S., Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J. Gene Med. 10 (2008), 518–526.
118. [118] Wang, Y., Huang, F., Cai, H., Wu, Y., He, G., Tan, W.S., The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 136 (2010), 1827–1837.
119. [119] Zhang, Y., Ma, H., Zhang, J., Liu, S., Liu, Y., Zheng, D., AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 82 (2008), 1154–1161.
120. [120] Jiang, M., Liu, Z., Xiang, Y., Ma, H., Liu, S., Liu, Y., Zheng, D., Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer, 11, 2011, 54.
121. [121] Chiu, T.L., Wang, M.J., Su, C.C., The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model. J. Biomed. Sci., 19, 2012, 45.
122. [122] Hamner, J.B., Sims, T.L., Cutshaw, A., Dickson, P.V., Rosati, S., McGee, M., Ng, C.Y., Davidoff, A.M., The efficacy of combination therapy using adeno-associated virus–interferon beta and trichostatin a in vitro and in a murine model of neuroblastoma. J. Pediatr. Surg. 43 (2008), 177–182 (discussion 182-173).
123. [123] Maguire, C.A., Meijer, D.H., LeRoy, S.G., Tierney, L.A., Broekman, M.L., Costa, F.F., Breakefield, X.O., Stemmer-Rachamimov, A., Sena-Esteves, M., Preventing growth of brain tumors by creating a zone of resistance. Mol. Ther. 16 (2008), 1695–1702.
124. [124] He, L.F., Wang, Y.G., Xiao, T., Zhang, K.J., Li, G.C., Gu, J.F., Chu, L., Tang, W.H., Tan, W.S., Liu, X.Y., Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter. Cancer Lett. 286 (2009), 196–205.
125. [125] Ren, C., Kumar, S., Chanda, D., Chen, J., Mountz, J.D., Ponnazhagan, S., Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26 (2008), 2332–2338.
126. [126] Wu, J.Q., Zhao, W.H., Li, Y., Zhu, B., Yin, K.S., Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy. Virology 368 (2007), 309–316.
127. [127] Xu, W., Xu, Y., Wei, Y., Tan, Y., Zhao, H., Zhao, W., Wu, J., Self-complementary adeno-associated virus 5-mediated gene transduction of a novel CD40L mutant confers direct antitumor effects in lung carcinoma. Mol. Med. Rep. 11 (2015), 482–488.
128. [128] Tahara, I., Miyake, K., Hanawa, H., Kurai, T., Hirai, Y., Ishizaki, M., Uchida, E., Tajiri, T., Shimada, T., Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol. Ther. 15 (2007), 1805–1811.
129. [129] Yang, Y.J., Chen, D.Z., Li, L.X., Sheng, Q.S., Jin, Z.K., Zhao, D.F., Targeted IL-24 gene therapy inhibits cancer recurrence after liver tumor resection by inducing tumor cell apoptosis in nude mice. Hepatobiliary Pancreat. Dis. Int. 8 (2009), 174–178.
130. [130] Tamai, H., Miyake, K., Yamaguchi, H., Takatori, M., Dan, K., Inokuchi, K., Shimada, T., AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood 119 (2012), 64–71.
131. [131] Chang, C.M., Lo, C.H., Shih, Y.M., Chen, Y., Wu, P.Y., Tsuneyama, K., Roffler, S.R., Tao, M.H., Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum. Gene Ther. 21 (2010), 611–621.
132. [132] Yiang, G.T., Chou, P.L., Tsai, H.F., Chen, L.A., Chang, W.J., Yu, Y.L., Wei, C.W., Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. Int. J. Mol. Med. 29 (2012), 809–814.
133. [133] Liang, C.M., Zhong, C.P., Sun, R.X., Liu, B.B., Huang, C., Qin, J., Zhou, S., Shan, J., Liu, Y.K., Ye, S.L., Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J. Virol. 81 (2007), 9502–9511.
134. [134] Buhles, A., Collins, S.A., van Pijkeren, J.P., Rajendran, S., Miles, M., O'Sullivan, G.C., O'Hanlon, D.M., Tangney, M., Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet. Vaccines Ther., 7, 2009, 5.
135. [135] Maitituoheti, M., Li, Y., Wang, W., Wang, W., Han, L., Yang, R., Wang, T., Wu, Z., Ma, D., Wang, S., Adeno-associated virus-mediated local delivery of LIGHT suppresses tumorigenesis in a murine cervical cancer model. J. Immunother. 34 (2011), 581–587.
136. [136] Driessens, G., Nuttin, L., Gras, A., Maetens, J., Mievis, S., Schoore, M., Velu, T., Tenenbaum, L., Preat, V., Bruyns, C., Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery. Cancer Immunol. Immunother. 60 (2011), 273–281.
137. [137] Ma, H., Zhang, Y., Wang, H., Han, C., Lei, R., Zhang, L., Yang, Z., Rao, L., Qing, H., Xiang, J., Deng, Y., Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma. Int. J. Mol. Sci. 15 (2014), 1–14.
138. [138] Tu, S.P., Cui, J.T., Liston, P., Huajiang, X., Xu, R., Lin, M.C., Zhu, Y.B., Zou, B., Ng, S.S., Jiang, S.H., Xia, H.H., Wong, W.M., Chan, A.O., Yuen, M.F., Lam, S.K., Kung, H.F., Wong, B.C., Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 128 (2005), 361–375.
139. [139] Xue, Z., Sun, P.H., Zhu, L.M., Jiang, S.H., Qiao, M.M., Chi, A.L., Tu, S.P., Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer. Oncol. Rep. 25 (2011), 1039–1046.
140. [140] Weng, Y., Fei, B., Chi, A.L., Cai, M., Inhibition of gastric cancer cell growth in vivo by overexpression of adeno-associated virus-mediated survivin mutant C84A. Oncol. Res. 20 (2013), 411–417.
141. [141] Dang, S.C., Feng, S., Wang, P.J., Cui, L., Qu, J.G., Zhang, J.X., Overexpression of survivin mutant Thr34Ala induces apoptosis and inhibits gastric cancer growth. Neoplasma 62 (2015), 81–87.
142. [142] Ng, S.S., Gao, Y., Chau, D.H., Li, G.H., Lai, L.H., Huang, P.T., Huang, C.F., Huang, J.J., Chen, Y.C., Kung, H.F., Lin, M.C., A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther. 14 (2007), 561–572.
143. [143] Gao, Y., Ng, S.S., Chau, D.H., Yao, H., Yang, C., Man, K., Huang, P.T., Huang, C., Huang, J.J., Kung, H.F., Lin, M.C., Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Ther. 15 (2008), 723–732.
144. [144] Watanabe, M., Nasu, Y., Kashiwakura, Y., Kusumi, N., Tamayose, K., Nagai, A., Sasano, T., Shimada, T., Daida, H., Kumon, H., Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum. Gene Ther. 16 (2005), 699–710.
145. [145] Li, J., Zhou, J., Chen, G., Wang, H., Wang, S., Xing, H., Gao, Q., Lu, Y., He, Y., Ma, D., Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther. 13 (2006), 266–272.
146. [146] Nie, B., Shen, Z., Wen, J.B., Wong, O.G., Hsueh, W.D., Huo, L.F., Kung, H.F., Jiang, B., Lin, M.C., AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer. Mol. Cancer Ther. 7 (2008), 2855–2865.
147. [147] Shah, G.V., Thomas, S., Muralidharan, A., Liu, Y., Hermonat, P.L., Williams, J., Chaudhary, J., Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways. Endocr. Relat. Cancer 15 (2008), 953–964.
148. [148] Chang, S.H., Kim, J.E., Lee, J.H., Minai-Tehrani, A., Han, K., Chae, C., Cho, Y.H., Yun, J.H., Park, K., Kim, Y.S., Cho, M.H., Aerosol delivery of eukaryotic translation initiation factor 4E-binding protein 1 effectively suppresses lung tumorigenesis in K-rasLA1 mice. Cancer Gene Ther. 20 (2013), 331–335.
149. [149] Wang, S., Wu, Y., Hou, Y., Guan, X., Castelvetere, M.P., Oblak, J.J., Banerjee, S., Filtz, T.M., Sarkar, F.H., Chen, X., Jena, B.P., Li, C., CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. Transl. Oncol. 6 (2013), 216–225.
150. [150] Yuan, L., Zhao, H., Zhang, L., Liu, X., The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumour Biol. 34 (2013), 3027–3034.
151. [151] Zhu, B., Li, X., Zhang, Y., Ye, C., Wang, Y., Cai, S., Huang, H., Cai, Y., Yeh, S., Huang, Z., Chen, R., Tao, Y., Wen, X., Cross-talk of alpha tocopherol-associated protein and JNK controls the oxidative stress-induced apoptosis in prostate cancer cells. Int. J. Cancer 132 (2013), 2270–2282.
152. [152] Ma, H.I., Hueng, D.Y., Shui, H.A., Han, J.M., Wang, C.H., Lai, Y.H., Cheng, S.Y., Xiao, X., Chen, M.T., Yang, Y.P., Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation. Int. J. Mol. Sci. 15 (2014), 4393–4414.
153. [153] Cheng, M., Ho, S., Yoo, J.H., Tran, D.H., Bakirtzi, K., Su, B., Tran, D.H., Kubota, Y., Ichikawa, R., Koon, H.W., Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts. Clin. Exp. Gastroenterol. 8 (2015), 13–29.
154. [154] Liao, Y.J., Fang, C.C., Yen, C.H., Hsu, S.M., Wang, C.K., Huang, S.F., Liang, Y.C., Lin, Y.Y., Chu, Y.T., Arthur Chen, Y.M., Niemann–Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: clinicopathological correlations and therapeutical implications. Int. J. Cancer, 2015.
155. [155] Pepin, D., Sosulski, A., Zhang, L., Wang, D., Vathipadiekal, V., Hendren, K., Coletti, C.M., Yu, A., Castro, C.M., Birrer, M.J., Gao, G., Donahoe, P.K., AAV9 delivering a modified human mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E4418–E4427.
156. [156] Ruifa, H., Liwei, L., Binxin, L., Ximing, L., Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Urol. Int. 77 (2006), 355–361.
157. [157] Neukirchen, J., Meier, A., Rohrbeck, A., Garcia-Pardillos, G., Steidl, U., Fenk, R., Haas, R., Kronenwett, R., Rohr, U.P., The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. Cancer Gene Ther. 14 (2007), 431–439.
158. [158] Qazilbash, M.H., Xiao, X., Seth, P., Cowan, K.H., Walsh, C.E., Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 4 (1997), 675–682.
159. [159] Li, X., Liu, X., Li, C.Y., Ding, Y., Chau, D., Li, G., Kung, H.F., Lin, M.C., Peng, Y., Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein–Barr virus encoded LMP-1. Int. J. Oncol. 29 (2006), 595–603.
160. [160] Wu, S., Meng, L., Wang, S., Wang, W., Xi, L., Tian, X., Chen, G., Wu, Y., Zhou, J., Xu, G., Lu, Y., Ma, D., Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA. Clin. Cancer Res. 12 (2006), 2032–2037.
161. [161] Sun, A., Tang, J., Terranova, P.F., Zhang, X., Thrasher, J.B., Li, B., Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study. Int. J. Cancer 126 (2010), 764–774.
162. [162] Zhang, K., Jiao, X., Liu, X., Zhang, B., Wang, J., Wang, Q., Tao, Y., Zhang, D., Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic agents and irradiation. Int. J. Mol. Sci. 11 (2010), 4891–4892.
163. [163] Zhang, K., Zhang, B., Lu, Y., Sun, C., Zhao, W., Jiao, X., Hu, J., Mu, P., Lu, H., Zhou, C., Slug inhibition upregulates radiation-induced PUMA activity leading to apoptosis in cholangiocarcinomas. Med. Oncol. 28:Suppl. 1 (2011), S301–S309.
164. [164] Wu, Y., Guo, Z., Zhang, D., Zhang, W., Yan, Q., Shi, X., Zhang, M., Zhao, Y., Zhang, Y., Jiang, B., Cheng, T., Bai, Y., Wang, J., A novel colon cancer gene therapy using rAAVmediated expression of human shRNA-FHL2. Int. J. Oncol. 43 (2013), 1618–1626.
165. [165] Li, L., Yang, L., Scudiero, D.A., Miller, S.A., Yu, Z.X., Stukenberg, P.T., Shoemaker, R.H., Kotin, R.M., Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther. 14 (2007), 814–827.
166. [166] Kota, J., Chivukula, R.R., O'Donnell, K.A., Wentzel, E.A., Montgomery, C.L., Hwang, H.W., Chang, T.C., Vivekanandan, P., Torbenson, M., Clark, K.R., Mendell, J.R., Mendell, J.T., Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137 (2009), 1005–1017.
167. [167] Liu, D.W., Chang, J.L., Tsao, Y.P., Huang, C.W., Kuo, S.W., Chen, S.L., Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int. J. Cancer 113 (2005), 93–100.
168. [168] Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J.A., Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16L1. J. Virol. 80 (2006), 2621–2630.
169. [169] Nieto, K., Kern, A., Leuchs, B., Gissmann, L., Muller, M., Kleinschmidt, J.A., Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antivir. Ther. 14 (2009), 1125–1137.
170. [170] Nieto, K., Stahl-Hennig, C., Leuchs, B., Muller, M., Gissmann, L., Kleinschmidt, J.A., Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum. Gene Ther. 23 (2012), 733–741.
171. [171] Zhou, L., Zhu, T., Ye, X., Yang, L., Wang, B., Liang, X., Lu, L., Tsao, Y.P., Chen, S.L., Li, J., Xiao, X., Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70. Hum. Gene Ther. 21 (2010), 109–119.
172. [172] Liao, S., Zhang, W., Hu, X., Wang, W., Deng, D., Wang, H., Wang, C., Zhou, J., Wang, S., Zhang, H., Ma, D., A novel “priming-boosting” strategy for immune interventions in cervical cancer. Mol. Immunol. 64 (2015), 295–305.
173. [173] Cesco-Gaspere, M., Zentilin, L., Giacca, M., Burrone, O.R., Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand. J. Immunol. 68 (2008), 58–66.
174. [174] Pan, J., Zhang, Q., Zhou, J., Ma, D., Xiao, X., Wang, D.W., Recombinant adeno-associated virus encoding Epstein–Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma. Mol. Cancer Ther. 8 (2009), 2754–2761.
175. [175] Triozzi, P.L., Aldrich, W., Ponnazhagan, S., Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine 28 (2010), 7837–7843.
176. [176] Triozzi, P.L., Aldrich, W., Ponnazhagan, S., Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists. Cancer Gene Ther. 18 (2011), 850–858.
177. [177] Steel, J.C., Di Pasquale, G., Ramlogan, C.A., Patel, V., Chiorini, J.A., Morris, J.C., Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer. Mol. Ther. 21 (2013), 680–687.
178. [178] Han, L., Wang, W., Lu, J., Kong, F., Ma, G., Zhu, Y., Zhao, D., Zhu, J., Shuai, W., Zhou, Q., Chen, P., Ye, L., Tao, J., Ahmad, S., Li, F., Sun, J., AAV-sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo. Cancer Lett. 354 (2014), 398–406.
179. [179] Ho, D.T., Wykoff-Clary, S., Gross, C.S., Schneider, D., Jin, F., Kretschmer, P.J., Hermiston, T.W., Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer Gene Ther. 16 (2009), 184–194.
180. [180] Lv, F., Qiu, Y., Zhang, Y., Liu, S., Shi, J., Liu, Y., Zheng, D., Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. Cancer Lett. 302 (2011), 119–127.
181. [181] Principe, M., Ceruti, P., Shih, N.Y., Chattaragada, M.S., Rolla, S., Conti, L., Bestagno, M., Zentilin, L., Yang, S.H., Migliorini, P., Cappello, P., Burrone, O., Novelli, F., Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget 6 (2015), 11098–11113.
182. [182] Di, L., Zhu, Y., Jia, J., Yu, J., Song, G., Zhang, J., Che, L., Yang, H., Han, Y., Ma, B., Zhang, C., Yuan, Y., You, M., Wan, F., Wang, X., Zhou, X., Ren, J., Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin. Transl. Oncol. 14 (2012), 675–681.
183. [183] Amer, M.H., Gene therapy for cancer: present status and future perspective. Mol. Cell. Ther., 2, 2014, 27.
184. [184] Hadaczek, P., Mirek, H., Berger, M.S., Bankiewicz, K., Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors. J. Neurosurg. 102 (2005), 328–335.
185. [185] Palucka, K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12 (2012), 265–277.
186. [186] Dougan, M., Dranoff, G., Immune therapy for cancer. Annu. Rev. Immunol. 27 (2009), 83–117.
187. [187] Kyi, C., Postow, M.A., Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588 (2014), 368–376.
188. [188] Fumoto, S., Kawakami, S., Hashida, M., Nishida, K., Targeted Gene Delivery: Importance of Administration Routes. 2013.
189. [189] Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., Chapman, M.S., The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10405–10410.
190. [190] Schrodinger, LLC, The PyMOL Molecular Graphics System, Version 1.3r1. 2010.